NEWS
The Next Tax Fight: SALT
Much ink has been spilled either criticizing or praising the bipartisan, bicameral Wyden-Smith tax deal. The bill makes many retroactive and mostly temporary changes, when sound tax policy should generally be prospective and permanent.
Alex Brill on Single-Payer Health Care System and Drug Costs
Alex Brill is a senior fellow at the American Enterprise Institute (AEI), where he studies the impact of tax policy on the US economy as well as the fiscal, economic, and political consequences of tax, budget, health care, retirement security, and trade policies.
New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023.
The Threat to Preferred Pharmacy Networks
Provider networks are a well-known tool health insurance companies use to keep down the cost of care.
Alex Brill mentioned on MSN
If the Supreme Court rules in their favor, it could open the door to reshaping the country’s tax code.
Alex Brill Speaks on Consequences of Proposed PBM Constraints
In December, MGA CEO Alex Brill participated in a RealClearPolitics event looking at the negative consequences of limiting the business practices of PBMs.
Patent Thicket Remedies
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
This Corporate Law Case Could Accidentally Overturn U.S. Taxes
This week, the Supreme Court will hear oral arguments in Moore v. United States, a case that centers on the mandatory repatriation tax (MRT).
Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
House lawmakers are expected to vote soon on an emergency supplemental funding bill to provide military support to Israel in its war against Hamas terrorists.
The Economics of “Delinking” PBM Compensation
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
The Supreme Court Should Leave the Tax Code Alone
We have submitted an amicus brief in support of the respondent (the US government) arguing that the MRT is constitutional as an indirect tax.
Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
Amicus Brief in Moore v. United States
In December, the Supreme Court will hear oral arguments in Moore v. United States, a case to determine whether the mandatory repatriation tax (MRT) is constitutional.
Biosimilars – Keys to Success in the Pharmacy Benefit
Alex Brill recently joined the GRx+Biosims 2023 conference panel to discuss biosimilars and the keys to success in the pharmacy benefit.
New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs.
- Despite Headwinds, Biosimilars Market Is Growing in 2024
- IRS says it will deny most claims of pandemic tax credit for employers
- Trump Talks Taxes and Tariffs
- Beware the Baseline Manipulator
- Patent Thicket Déjà Vu
- Will Congress Finally Act on Patent Thickets?
- Federal Debt: The Baseline and Options for Reform
- Navigating the Upcoming Tax Cliff: Can Republicans Prevent a Tax Increase Without Adding to the Deficit?
- Current and Future State of US Biosimilars
- Trends in the US Insulin Market: New Prices, New Players, New Dynamics
